These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

155 related items for PubMed ID: 8875978

  • 1. Inhibition of intratracheal lung cancer development by systemic delivery of E1A.
    Chang JY, Xia W, Shao R, Hung MC.
    Oncogene; 1996 Oct 03; 13(7):1405-12. PubMed ID: 8875978
    [Abstract] [Full Text] [Related]

  • 2. HER-2/neu-targeting cancer therapy via adenovirus-mediated E1A delivery in an animal model.
    Zhang Y, Yu D, Xia W, Hung MC.
    Oncogene; 1995 May 18; 10(10):1947-54. PubMed ID: 7761095
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. [Down regulation of HER2/neu expression by adenovirus E1A and its anti-tumor activity].
    Lu H, Qin H, Zhang Y.
    Zhonghua Zhong Liu Za Zhi; 2000 Sep 18; 22(5):370-3. PubMed ID: 11778270
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Cancer therapy utilizing an adenoviral vector expressing only E1A.
    Hubberstey AV, Pavliv M, Parks RJ.
    Cancer Gene Ther; 2002 Apr 18; 9(4):321-9. PubMed ID: 11960282
    [Abstract] [Full Text] [Related]

  • 12. A survivin-mediated oncolytic adenovirus induces non-apoptotic cell death in lung cancer cells and shows antitumoral potential in vivo.
    Li B, Liu X, Fan J, Qi R, Bo L, Gu J, Qian Q, Qian C, Liu X.
    J Gene Med; 2006 Oct 18; 8(10):1232-42. PubMed ID: 16900558
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Gene therapy with secretory leukoprotease inhibitor promoter-controlled replication-competent adenovirus for non-small cell lung cancer.
    Maemondo M, Saijo Y, Narumi K, Kikuchi T, Usui K, Tazawa R, Matsumoto K, Nakamura T, Sasaki K, Takahashi M, Niitsu Y, Nukiwa T.
    Cancer Res; 2004 Jul 01; 64(13):4611-20. PubMed ID: 15231673
    [Abstract] [Full Text] [Related]

  • 15. Adenovirus E1a-mediated tumor suppression by a c-erbB-2/neu-independent mechanism.
    Frisch SM, Dolter KE.
    Cancer Res; 1995 Dec 01; 55(23):5551-5. PubMed ID: 7585633
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Mutant SV40 large T antigen as a therapeutic agent for HER-2/neu-overexpressing ovarian cancer.
    Xing X, Matin A, Yu D, Xia W, Sorgi F, Huang L, Hung MC.
    Cancer Gene Ther; 1996 Dec 01; 3(3):168-74. PubMed ID: 8725881
    [Abstract] [Full Text] [Related]

  • 18. Safety studies of the intraperitoneal injection of E1A--liposome complex in mice.
    Xing X, Liu V, Xia W, Stephens LC, Huang L, Lopez-Berestein G, Hung MC.
    Gene Ther; 1997 Mar 01; 4(3):238-43. PubMed ID: 9135737
    [Abstract] [Full Text] [Related]

  • 19. Tyrosine kinase inhibitor emodin suppresses growth of HER-2/neu-overexpressing breast cancer cells in athymic mice and sensitizes these cells to the inhibitory effect of paclitaxel.
    Zhang L, Lau YK, Xia W, Hortobagyi GN, Hung MC.
    Clin Cancer Res; 1999 Feb 01; 5(2):343-53. PubMed ID: 10037184
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.